Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Neuroblastoma 3Lymphoma 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Unspecified Childhood Solid Tumor, Protocol Specific 1Subcutaneous panniculitis-like T-cell lymphoma 1Sertoli-Leydig Cell Tumor 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian gynandroblastoma 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Leukemia 1Immunoblastic Lymphadenopathy 1Granulosa cell tumor of the ovary 1Glioma 1Fallopian Tube Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Ovarian Epithelial 1

Interventions

prednylidene 1pirarubicin 1etoposide phosphate 1Vincristine 1Prednisone 1Methotrexate 1Ifosfamide 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Subcutaneous panniculitis-like T-cell lymphoma × etoposide phosphate × Clear all
NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡